Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 10 | 2025 | 215 | 2.200 |
Why?
|
| Colitis, Ulcerative | 6 | 2024 | 118 | 1.550 |
Why?
|
| Inflammatory Bowel Diseases | 9 | 2024 | 320 | 1.530 |
Why?
|
| Weight Loss | 2 | 2023 | 732 | 0.440 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 70 | 0.420 |
Why?
|
| Diarrhea | 1 | 2013 | 180 | 0.400 |
Why?
|
| Internship and Residency | 1 | 2020 | 1047 | 0.350 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2003 | 0.300 |
Why?
|
| Intestinal Mucosa | 2 | 2025 | 589 | 0.290 |
Why?
|
| Adenocarcinoma | 3 | 2021 | 898 | 0.280 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2025 | 640 | 0.270 |
Why?
|
| Leukopenia | 1 | 2024 | 28 | 0.230 |
Why?
|
| Phagocytes | 1 | 2025 | 97 | 0.230 |
Why?
|
| Pyrophosphatases | 1 | 2024 | 22 | 0.230 |
Why?
|
| Stromal Cells | 1 | 2024 | 105 | 0.220 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 2740 | 0.210 |
Why?
|
| Physical Examination | 1 | 2023 | 234 | 0.190 |
Why?
|
| Feces | 1 | 2024 | 441 | 0.190 |
Why?
|
| Flow Cytometry | 1 | 2024 | 1155 | 0.170 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2021 | 71 | 0.170 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 752 | 0.170 |
Why?
|
| Environmental Exposure | 1 | 2024 | 462 | 0.160 |
Why?
|
| Precancerous Conditions | 1 | 2021 | 163 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 259 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2020 | 204 | 0.150 |
Why?
|
| Proteomics | 1 | 2024 | 1054 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 181 | 0.140 |
Why?
|
| Adult | 13 | 2025 | 35495 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 242 | 0.140 |
Why?
|
| Humans | 20 | 2025 | 129266 | 0.140 |
Why?
|
| Counseling | 1 | 2020 | 383 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 848 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2515 | 0.130 |
Why?
|
| Male | 16 | 2025 | 63512 | 0.120 |
Why?
|
| Middle Aged | 12 | 2025 | 31090 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2018 | 236 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 756 | 0.120 |
Why?
|
| Young Adult | 7 | 2025 | 12391 | 0.120 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 84 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2025 | 485 | 0.110 |
Why?
|
| Polyomavirus | 1 | 2014 | 12 | 0.110 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 27 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 46 | 0.110 |
Why?
|
| Inflammation | 1 | 2025 | 2737 | 0.110 |
Why?
|
| Curriculum | 1 | 2020 | 910 | 0.110 |
Why?
|
| Risk Factors | 4 | 2024 | 9745 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 46 | 0.110 |
Why?
|
| Psychotropic Drugs | 1 | 2014 | 69 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 400 | 0.100 |
Why?
|
| Pelvis | 1 | 2013 | 104 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 1202 | 0.100 |
Why?
|
| Transplant Recipients | 1 | 2014 | 162 | 0.100 |
Why?
|
| Female | 13 | 2025 | 68551 | 0.100 |
Why?
|
| Aged | 7 | 2024 | 22032 | 0.100 |
Why?
|
| Colon | 2 | 2024 | 252 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2013 | 156 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2014 | 366 | 0.090 |
Why?
|
| Biomarkers | 4 | 2024 | 3968 | 0.090 |
Why?
|
| Cholestasis | 1 | 2013 | 232 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2013 | 290 | 0.090 |
Why?
|
| Hospitalization | 2 | 2020 | 2052 | 0.080 |
Why?
|
| Registries | 3 | 2022 | 1895 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2022 | 7123 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2025 | 3377 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 2439 | 0.060 |
Why?
|
| Disease Progression | 1 | 2013 | 2630 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2013 | 831 | 0.060 |
Why?
|
| Clostridiales | 1 | 2025 | 1 | 0.060 |
Why?
|
| Faecalibacterium | 1 | 2024 | 1 | 0.060 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2024 | 16 | 0.060 |
Why?
|
| Indians, South American | 1 | 2024 | 23 | 0.060 |
Why?
|
| Dietary Fiber | 1 | 2024 | 51 | 0.060 |
Why?
|
| Ileum | 1 | 2025 | 115 | 0.060 |
Why?
|
| Methyltransferases | 1 | 2024 | 70 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 3628 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 172 | 0.050 |
Why?
|
| Alaska Natives | 1 | 2024 | 138 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 476 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2013 | 2473 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 427 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2025 | 766 | 0.040 |
Why?
|
| Biopsy | 1 | 2024 | 1092 | 0.040 |
Why?
|
| Mesalamine | 1 | 2020 | 10 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2020 | 105 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2024 | 5409 | 0.040 |
Why?
|
| Quality of Life | 2 | 2022 | 2687 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 815 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 496 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7055 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 14461 | 0.040 |
Why?
|
| Adolescent | 3 | 2024 | 20313 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 230 | 0.040 |
Why?
|
| Bacteria | 1 | 2024 | 813 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 776 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 5384 | 0.040 |
Why?
|
| Biological Products | 1 | 2020 | 200 | 0.030 |
Why?
|
| Diet | 1 | 2024 | 1212 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2020 | 605 | 0.030 |
Why?
|
| Age Factors | 1 | 2024 | 3140 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 2276 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2014 | 82 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 145 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 105 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 757 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2553 | 0.030 |
Why?
|
| Exanthema | 1 | 2014 | 74 | 0.030 |
Why?
|
| Viremia | 1 | 2014 | 131 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 851 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 91 | 0.030 |
Why?
|
| Colectomy | 1 | 2013 | 93 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 198 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2013 | 185 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2013 | 198 | 0.020 |
Why?
|
| Child | 2 | 2024 | 20785 | 0.020 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2013 | 83 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1497 | 0.020 |
Why?
|
| Endoscopy | 1 | 2014 | 285 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 991 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1197 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1199 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1691 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 3710 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 726 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 10459 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1965 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 2636 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 4887 | 0.010 |
Why?
|